Lé, Ana Maria
Puig, Luis http://orcid.org/0000-0001-6083-0952
Torres, Tiago http://orcid.org/0000-0003-0404-0870
Article History
Accepted: 25 July 2022
First Online: 12 August 2022
Declarations
:
: AML, LP and TT had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work.
: No funding was received for the preparation of this manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: Ana Maria Lé has no conflicts of interest. Luis Puig has served as a scientific adviser and/or clinical study investigator for, or has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, JS BIOCAD, LEO Pharma, Lilly, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi and UCB. Tiago Torres has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz and UCB.
: Not applicable.
Free to read: This content has been made available to all.